NAC drops to improve cornea disease during cataract surgery
Part of Eyes & vision, Genetic & congenital clinical trials.
This Phase 2 study tests whether eye drops containing a medicine called N-acetylcysteine (NAC) can reduce damaging “reactive oxygen” in people with advanced Fuchs’ endothelial corneal dystrophy (FECD). It involves people who need a special cornea transplant (DMEK) at the same time as cataract surgery, aiming to improve cornea healing and vision.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 21 years or older (checked at the time of your surgery visit).
- You have advanced FECD and cataract that affects your vision.
- You are scheduled to have DMEK (cornea transplant) and cataract surgery together.
- You can sign consent and follow the study visit and medication schedule.
- You are willing and able to use the study eye drops exactly as instructed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether special eye drops (Rho-kinase inhibitors) can improve the health of the cornea in people who have both Fuchs endothelial corneal dystrophy and glaucoma. The drops may help reduce corneal swelling and preserve your vision.
This trial tests a special intraocular lens that works with a cornea transplant procedure (DMEK) for people who have both cataracts and Fuchs' endothelial corneal dystrophy. It aims to see if this lens improves vision and reduces the need for glasses.
This study tests a scoring system to predict how well people with Fuchs dystrophy do after cataract surgery. It may help doctors plan better treatment for your cornea and lens.
This study measures corneal thickness after cataract surgery in people with and without Fuchs' endothelial dystrophy (a condition that can cause cloudy vision). It may help doctors understand how the cornea heals after surgery.
This trial tests an investigational eye drop (DT-168) in people with Fuchs endothelial corneal dystrophy who are already scheduled for a corneal transplant. The goal is to see if DT-168 can improve outcomes or delay the need for surgery.
This trial tests an eye drop called CA201A to see if it can prevent loss of cells in the clear front layer of the eye (the cornea) after cataract surgery. The drop contains ascorbic acid, a form of vitamin C, and is given before and after the procedure to help protect the eyesight.
Hear when a new Fuchs Endothelial Corneal Dystrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.